Hypertension Research最新文献_第2页

Serum uric acid is independently associated with impaired nitroglycerine-induced vasodilation of the brachial artery in women. 血清尿酸与硝酸甘油诱导的女性肱动脉血管扩张受损有独立关联。

IF 4.3 2区医学

Hypertension Research Pub Date : 2024-11-14 DOI: 10.1038/s41440-024-01972-5

Tatsuya Maruhashi, Masato Kajikawa, Shinji Kishimoto, Takayuki Yamaji, Takahiro Harada, Aya Mizobuchi, Shunsuke Tanigawa, Farina Mohamad Yusoff, Yukiko Nakano, Kazuaki Chayama, Ayumu Nakashima, Chikara Goto, Yukihito Higashi

{"title":"Serum uric acid is independently associated with impaired nitroglycerine-induced vasodilation of the brachial artery in women.","authors":"Tatsuya Maruhashi, Masato Kajikawa, Shinji Kishimoto, Takayuki Yamaji, Takahiro Harada, Aya Mizobuchi, Shunsuke Tanigawa, Farina Mohamad Yusoff, Yukiko Nakano, Kazuaki Chayama, Ayumu Nakashima, Chikara Goto, Yukihito Higashi","doi":"10.1038/s41440-024-01972-5","DOIUrl":"https://doi.org/10.1038/s41440-024-01972-5","url":null,"abstract":"Experimental and clinical studies have suggested atherosclerotic effects of uric acid (UA) on vascular smooth muscle cells (VSMCs). Nitroglycerine-induced vasodilation (NID), a control test for flow-mediated vasodilation, can be used as a possible marker of VSMC dysfunction. However, there is little information on the association between UA and NID. Therefore, we investigated the association between serum UA levels and NID according to sex. We measured NID of the brachial artery in 598 women (mean age: 66.2 ± 12.0 years) and 1008 men (mean age: 59.0 ± 18.0 years). In women, the mean serum UA level was 5.06 ± 1.24 mg/dL. Serum UA levels were negatively correlated with NID (p < 0.001), and NID significantly decreased with increasing serum UA levels (≤4.0 mg/dL, 13.4 ± 6.4%; 4.0 to ≤5.0 mg/dL, 11.4 ± 5.3%; 5.0 to ≤6.0 mg/dL, 10.8 ± 5.7%; >6.0 mg/dL, 9.7 ± 5.7%; p < 0.001). The prevalence of VSMC dysfunction, defined as NID < 8.4%, the division points for the lowest and middle tertiles of NID in women, increased with increasing serum UA levels ( ≤ 4.0 mg/dL, 23.3%; 4.0 to ≤5.0 mg/dL, 30.9%; 5.0 to ≤6.0 mg/dL, 36.4%; >6.0 mg/dL, 44.6%; p < 0.001). Multiple logistic regression analysis showed a significant association between serum UA levels and VSMC dysfunction (odds ratio, 1.21; 95% confidence interval, 1.02─1.43; p = 0.03). There was no interaction between age (<50 or ≥50 years) and the effect of serum UA levels on VSMC dysfunction (p interaction = 0.88). In contrast, no association was observed between serum UA levels and NID in men. Serum UA levels were significantly associated with VSMC dysfunction as assessed by NID in women.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nonsteroidal MR antagonism in PA: clinical outcomes and unanswered questions. PA 中的非类固醇 MR 拮抗剂：临床结果和未解之谜。

IF 4.3 2区医学

Hypertension Research Pub Date : 2024-11-14 DOI: 10.1038/s41440-024-02002-0

Daigoro Hirohama, Shigeru Shibata

引用次数: 0

Approaching the paradoxical relationship between hypertensive disorders of pregnancy and cerebral palsy among infants born very preterm with very low birth weight. 探讨妊娠高血压疾病与早产儿和极低出生体重儿脑瘫之间的矛盾关系。

IF 4.3 2区医学

Hypertension Research Pub Date : 2024-11-14 DOI: 10.1038/s41440-024-02007-9

Makiko Abe, Hisatomi Arima

引用次数: 0

The brain and hypertension: how the brain regulates and suffers from blood pressure. 大脑与高血压：大脑如何调节血压以及如何受到血压的影响。

IF 4.3 2区医学

Hypertension Research Pub Date : 2024-11-14 DOI: 10.1038/s41440-024-01990-3

Keisuke Shinohara

{"title":"The brain and hypertension: how the brain regulates and suffers from blood pressure.","authors":"Keisuke Shinohara","doi":"10.1038/s41440-024-01990-3","DOIUrl":"https://doi.org/10.1038/s41440-024-01990-3","url":null,"abstract":"The brain plays several roles in the relationship between blood pressure (BP) and the brain: it acts as the control center for BP regulation, a target organ in hypertension, and a crucial component for cognitive function. This mini-review introduces recent findings on \"brain and hypertension\" from Hypertension Research and other journals. Activation of the angiotensin II type 1 receptor (AT1R) signaling pathway in the brain causes sympathoexcitation and hypertension. AT1R-associated protein and β-arrestin promote AT1R internalization and suppress AT1R signaling, with brain-specific roles in BP regulation. The brain receives various inputs from the peripheral system, including the heart and kidneys, and controls central sympathetic outflow. The brain mechanism involved in the enhanced cardiac sympathetic afferent reflex and the beneficial effects of renal denervation have been demonstrated. The brain's vulnerability in hypertension includes stroke, with cerebral small vessel disease (SVD) contributing to stroke risk and brain changes. Sex differences and the age of hypertension onset influence these outcomes. High salt intake exacerbates hypertension and stroke risk, with central mechanisms like sympathoexcitation implicated. Hypertension significantly impacts cognitive function, linking to cerebral SVD and cognitive decline. Orthostatic BP regulation abnormalities also emerge as early risk markers for dementia. Improved BP control in hypertensive individuals can significantly reduce the risk of stroke and cognitive decline, as well as cardiovascular disease, enhancing overall brain health and quality of life. Further understanding the brain's role in BP regulation and the pathogenesis of hypertension will facilitate the development of novel hypertension treatments and prevention strategies.","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Serum uric acid level mirrors arterial stiffness in women: a window for her cardiovascular risk assessment? 血清尿酸水平反映了女性的动脉僵化：她的心血管风险评估窗口？

IF 4.3 2区医学

Hypertension Research Pub Date : 2024-11-14 DOI: 10.1038/s41440-024-02012-y

Atsushi Tanaka, Koichi Node

引用次数: 0

Beyond pharmacotherapy: bilateral adrenal artery embolization as a potential game-changer for idiopathic hyperaldosteronism patients. 药物治疗之外：双侧肾上腺动脉栓塞术有望改变特发性醛固酮过多症患者的命运。

IF 4.3 2区医学

Hypertension Research Pub Date : 2024-11-14 DOI: 10.1038/s41440-024-01984-1

Hironobu Umakoshi

引用次数: 0

Is a high serum uric acid level a cause or a bystander of hypertension? 血清尿酸水平高是高血压的诱因还是旁观者？

IF 4.3 2区医学

Hypertension Research Pub Date : 2024-11-14 DOI: 10.1038/s41440-024-02004-y

Tsuneo Konta

引用次数: 0

Is calculation of a home blood pressure-based stability score a tool to improve risk stratification in clinical practice? 在临床实践中，计算基于家庭血压的稳定性评分是否是改善风险分层的工具？

IF 4.3 2区医学

Hypertension Research Pub Date : 2024-11-14 DOI: 10.1038/s41440-024-02021-x

Tine Willum Hansen

引用次数: 0

Target organ damage in primary aldosteronism and captopril challenge test. 原发性醛固酮增多症的靶器官损伤和卡托普利挑战试验。

IF 4.3 2区医学

Hypertension Research Pub Date : 2024-11-14 DOI: 10.1038/s41440-024-02005-x

Akihiro Tojo

引用次数: 0

Cross talk on therapeutic strategies: natriuretic peptides and inhibiting neprilysin in hypertension management. 治疗策略的交叉对话：高血压治疗中的利钠肽和抑制肾酶。

IF 4.3 2区医学

Hypertension Research Pub Date : 2024-11-14 DOI: 10.1038/s41440-024-01989-w

Maya K Jangid, Gaurav M Doshi

{"title":"Cross talk on therapeutic strategies: natriuretic peptides and inhibiting neprilysin in hypertension management.","authors":"Maya K Jangid, Gaurav M Doshi","doi":"10.1038/s41440-024-01989-w","DOIUrl":"10.1038/s41440-024-01989-w","url":null,"abstract":"Hypertension, a prevalent cardiovascular condition globally, remains a significant public health concern due to its association with increased cardiovascular morbidity and mortality. Despite the availability of various antihypertensive therapies, achieving optimal blood pressure control in patients remains a challenge. Valsartan/sacubitril (ARNi), marketed as Entresto by Novartis, combines valsartan, an angiotensin receptor blocker, with sacubitril, an inhibitor of neprilysin. Neprilysin is responsible for breaking down natriuretic peptides and other vasoactive substances. Inhibiting neprilysin prevents the degradation of natriuretic peptides, enhancing their beneficial effects on blood pressure regulation. Natriuretic Peptides, including atrial natriuretic peptide (ANP) and brain natriuretic peptides (BNP), play pivotal roles in regulating blood pressure and cardiovascular homeostasis by promoting vasodilation, natriuresis, and antagonizing the renin-angiotensin-aldosterone system. Therefore, this combo drug lessens sensitivity to natriuretic peptides and tackles the processes in hypertension that activate the renin-angiotensin-aldosterone system. This review provides an overview of how natriuretic peptides (NPs) contribute to blood pressure regulation for the treatment of hypertension through inhibiting neprilysin. It highlights the ARNi's dual action that works synergistically by blocking the harmful effects of angiotensin II on blood vessels while simultaneously increasing the levels of beneficial natriuretic peptides. Schematic representation of the mechanism of action of ARNi. Abbreviation: -Renin angiotensin aldosterone system (RAAS), Natriuretic peptides (NP), Atrial Natriuretic peptide (ANP), Brain natriuretic peptide (BNP), C-type natriuretic peptide (CNP), Angiotensin II (Ang II), Angiotensin receptor neprilysin inhibitor (ARNI).","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142619166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0